Publication of a prospectus relating to the fully underwritten new rights issue in Diamyd Medical AB
The Board of Directors of Diamyd Medical AB (publ) has prepared a prospectus relating to the new issue of just under 220 MSEK with preferential rights for existing shareholders. The prospectus is available in Swedish on Diamyd Medical’s website www.diamyd.com.Summary of conditions for the new issue: - The new issue includes a maximum of 3,131,091 shares, whereof up to 157,267 are A shares and up to 2,973,824 are B shares - The issue price is 70 SEK per share, which means that the company receives up to 219,176,370 SEK before issue and guarantee costs - Every twenty-five (25) existing shares